Half a million genomes
GlaxoSmithKline and Regeneron will study the DNA of 500 thousand Britons
GlaxoSmithKline and Regeneron Pharmaceuticals presented a joint project with the UK Biobank, which aims to find new opportunities for the treatment of various diseases. The project will analyze the relationship between genetic variability and the health of 500,000 UK residents, according to Reuters (GSK and Regeneron to mine gene data from 500,000 Britons).
By the end of 2017, the Regeneron genome sequencing center will analyze the first 50,000 samples from the UK Biobank. The whole project is designed for 3-5 years. Based on its results, the partners hope to identify new clues for the creation of therapy for hereditary diseases. The project will use blood samples provided by UK Biobank volunteers aged 40-69 years in 2006-2010.
As part of the agreement, GlaxoSmithKline and Regeneron received the right to exclusive use for 9 months of all discoveries made during the project. After the expiration of the 9-month period, the data will be open to other scientists and researchers. At the same time, companies will incur costs only for the transportation and processing of samples, UK Biobank does not intend to charge pharmaceutical companies any payments.
A year ago, AstraZeneca entered into a similar agreement with Human Longevity, a company founded by Craig Venter. Then it was reported that the companies intend to study the genetic information of 2 million people in 10 years.
Portal "Eternal youth" http://vechnayamolodost.ru
23.03.2017